GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Debt-to-Equity

Halberd (Halberd) Debt-to-Equity : -0.16 (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Debt-to-Equity?

Halberd's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $0.00 Mil. Halberd's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $0.15 Mil. Halberd's Total Stockholders Equity for the quarter that ended in Jul. 2023 was $-0.93 Mil. Halberd's debt to equity for the quarter that ended in Jul. 2023 was -0.16.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Halberd's Debt-to-Equity or its related term are showing as below:

HALB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.21   Med: -0.18   Max: -0.16
Current: -0.16

During the past 3 years, the highest Debt-to-Equity Ratio of Halberd was -0.16. The lowest was -0.21. And the median was -0.18.

HALB's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs HALB: -0.16

Halberd Debt-to-Equity Historical Data

The historical data trend for Halberd's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Debt-to-Equity Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Debt-to-Equity
-8.64 -0.21 -0.16

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Debt-to-Equity -8.64 -0.21 -0.16

Competitive Comparison of Halberd's Debt-to-Equity

For the Biotechnology subindustry, Halberd's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Halberd's Debt-to-Equity falls into.


Halberd Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Halberd's Debt to Equity Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0.15) / -0.926
=-0.16

Halberd's Debt to Equity Ratio for the quarter that ended in Jul. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0.15) / -0.926
=-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd  (OTCPK:HALB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Halberd Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Halberd's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Debt-to-Equity
Comparable Companies
TSSI SWMM SFHI VSR ETOLF ESOA ENG LYOPF BBHDF RCMT LMB CUUHF GV IBIBF LAYN EMFGF LOUIF ORN WLDN GLDD
Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Website
https://www.halberdcorporation.com
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236